Drugs / PCV13-DT/TT
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06608199 | Nov 2024 → Jun 2025 overdue | pneumococcal infection | Beijing Minhai Biotechnology Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PCV13-DT/TT | “Minhai's 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13-DT/TT) as compared to Pfizer's 13-valent Pneumococcal Conjugate Vaccine (PCV13)” NCT06608199 ↗ |
| Known as | Pneuminvac | “novel PCV13-DT/TT (Pneuminvac)” NCT06608199 ↗ |
| Modality | Vaccine | “13-valent Pneumococcal Polysaccharide Conjugate Vaccine” NCT06608199 ↗ |